First Trust Advisors LP Acquires 132,943 Shares of Hologic, Inc. (NASDAQ:HOLX)

First Trust Advisors LP grew its holdings in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 75.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 308,979 shares of the medical equipment provider's stock after acquiring an additional 132,943 shares during the quarter. First Trust Advisors LP owned 0.14% of Hologic worth $22,274,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the business. Geode Capital Management LLC increased its holdings in shares of Hologic by 2.6% in the fourth quarter. Geode Capital Management LLC now owns 5,732,131 shares of the medical equipment provider's stock worth $412,159,000 after acquiring an additional 144,838 shares in the last quarter. Victory Capital Management Inc. increased its holdings in shares of Hologic by 0.5% in the fourth quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider's stock worth $354,506,000 after acquiring an additional 24,358 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in shares of Hologic by 3.0% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,403,220 shares of the medical equipment provider's stock worth $322,272,000 after acquiring an additional 129,035 shares in the last quarter. Invesco Ltd. increased its holdings in shares of Hologic by 16.4% in the fourth quarter. Invesco Ltd. now owns 4,070,384 shares of the medical equipment provider's stock worth $293,434,000 after acquiring an additional 572,187 shares in the last quarter. Finally, Boston Partners increased its holdings in shares of Hologic by 81.0% in the fourth quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock worth $257,959,000 after acquiring an additional 1,602,463 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors.

Hologic Price Performance

Hologic stock traded up $0.28 during mid-day trading on Tuesday, reaching $58.36. 1,552,009 shares of the company were exchanged, compared to its average volume of 1,967,219. The company has a fifty day simple moving average of $60.90 and a 200-day simple moving average of $69.77. Hologic, Inc. has a 12 month low of $55.89 and a 12 month high of $84.67. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The firm has a market cap of $13.10 billion, a PE ratio of 18.41, a PEG ratio of 2.14 and a beta of 0.82.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. As a group, equities research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on HOLX. Leerink Partners cut Hologic from an "outperform" rating to a "market perform" rating and reduced their price objective for the stock from $80.00 to $75.00 in a research report on Thursday, February 6th. William Blair reissued an "outperform" rating on shares of Hologic in a research report on Thursday, February 6th. Leerink Partnrs cut Hologic from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 6th. Stephens reaffirmed an "overweight" rating and issued a $84.00 price objective on shares of Hologic in a research report on Thursday, February 6th. Finally, Citigroup cut their price objective on Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Eleven research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Hologic currently has a consensus rating of "Hold" and an average target price of $84.62.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.